ArticleBMJ open2025

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)-a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol.

Eugenia Negredo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.